LianBio partner NANOBIOTIX enters license agreement with JanssenJohnson & Johnson

LianBio (LIAN) announced that partner Nanobiotix has entered into a license agreement with Janssen Pharmaceutica (JNJ) for the investigational, potential first-in-class radioenhancer NBTXR3. Nanobiotix will grant Janssen a worldwide license for the co-development and commercialization of NBTXR3. The license is exclusive, excepting territories previously licensed to LianBio. Details and financial terms of the Nanobiotix and Janssen collaboration are available on the investor section of the Nanobiotix website. LianBio licensed rights from Nanobiotix in May 2021 for the development and commercialization of NBTXR3 in Mainland China, Hong Kong, Macau, Taiwan, Thailand, South Korea, and Singapore. LianBio and Nanobiotix are currently enrolling patients in NANORAY-312, a global Phase 3 trial designed to investigate the efficacy and safety of radiotherapy-activated NBTXR3 with or without cetuximab versus radiotherapy with or without cetuximab in high-risk, chemotherapy-ineligible elderly patients with locally advanced head and neck squamous cell carcinoma. Eligible participants for NANORAY-312 will be treated with NBTXR3 at a 1:1 ratio after an Investigator’s Choice of radiotherapy alone or radiotherapy in combination with cetuximab. This pivotal trial is expected to enroll 500 patients globally, with approximately 100 patients in LianBio’s licensed territories expected to participate in the study.